Ponatinib
Ariad begins Phase 2 trial of Iclusig to treat GI tumors
Boston Business Journal (blog)
Ariad Pharmaceuticals, Inc. has launched a Phase 2 trial to test its approved leukemia drug Iclusig as a potential treatment for gastrointestinal stromal tumors (GIST).
The Cambridge, Mass-based company’s drug was approved by the U.S. Food and Drug Administration in December 2012. It’s approved to treat certain patients chronic myeloid leukemia (CML) that is resistant or intolerant to other drugs and Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL).
read all at
http://www.bizjournals.com/boston/blog/bioflash/2013/06/ariad-trial-cancer-drug.html
